Given the limited success of AD treatments focused on targeting Aβ plaques or Tau tangles, modulating mitochondrial Ca2+ levels by targeting influx and efflux pathways (e.g., MCU, NCLX, or LETM1) presents a promising alternative approach that warrants further investigation. The gene discussed is SLC8B1; the disease is Alzheimer disease.